These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7831665)

  • 41. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enoxaparin: pharmacokinetics and treatment schedule for cats.
    Mischke R; Schönig J; Döderlein E; Wolken S; Böhm C; Kietzmann M
    Vet J; 2014 Jun; 200(3):375-81. PubMed ID: 24810867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates.
    Jeske W; Litinas E; Khan H; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2012 Jun; 18(3):294-8. PubMed ID: 22275388
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization with a simple clotting assay of the tissue factor inhibiting activity in serum.
    Cassetti M; Minestrini D; Palazzesi G
    Haematologica; 1990; 75(1):32-7. PubMed ID: 2242114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacokinetics of heparin after a single intravenous or subcutaneous injection].
    Mombelli G; Schaedelin J; Beck EA
    Schweiz Med Wochenschr; 1977 Jun; 107(23):810-5. PubMed ID: 877532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacological activities of heparins obtained from different tissues: enrichment of heparin fractions with high lipoprotein lipase, antihemolytic and anticoagulant activities by molecular sieving and antithrombin III affinity chromatography.
    Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP
    J Pharmacol Exp Ther; 1982 Feb; 220(2):406-10. PubMed ID: 7057400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and bioactivity of copolymers with fragments of heparin.
    Mazid MA; Moase E; Scott E; Hanna HR; Unger FM
    J Biomed Mater Res; 1991 Sep; 25(9):1169-81. PubMed ID: 1779000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A simple test for the monitoring of plasma anti-XA activity of patients following subcutaneous administration of enoxaparin].
    Halbmayer WM; Feichtinger C; Schwarz T; Gschnait F; Strasser A; Priesching A; Fischer M
    Wien Klin Wochenschr; 1990 Jul; 102(14):408-13. PubMed ID: 2166377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine.
    Dawes J; Prowse CV; Pepper DS
    Thromb Haemost; 1985 Oct; 54(3):630-4. PubMed ID: 2935965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest).
    Bara L; Combe-Tamzali S; Conard J; Horellou MH; Samama M
    Haemostasis; 1987; 17(3):127-33. PubMed ID: 3609913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of pharmacokinetic variables for two low-molecular-weight heparins after subcutaneous administration of a single dose to horses.
    Schwarzwald CC; Feige K; Wunderli-Allenspach H; Braun U
    Am J Vet Res; 2002 Jun; 63(6):868-73. PubMed ID: 12061534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma.
    Al-Sallami HS; Medlicott NJ
    J Pharm Pharmacol; 2015 Feb; 67(2):209-14. PubMed ID: 25557692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans.
    de Swart CA; Nijmeyer B; Andersson LO; Holmer E; Sixma JJ; Bouma BN
    Thromb Haemost; 1984 Aug; 52(1):66-70. PubMed ID: 6495266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ion exchange chromatographic separation and isolation of oligosaccharides of intact low-molecular-weight heparin for the determination of their anticoagulant and anti-inflammatory properties.
    Shastri MD; Johns C; Hutchinson JP; Khandagale M; Patel RP
    Anal Bioanal Chem; 2013 Jul; 405(18):6043-52. PubMed ID: 23712644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Purification, characterization and in vivo studies of salmon heparin.
    Flengsrud R; Larsen ML; Ødegaard OR
    Thromb Res; 2010 Dec; 126(6):e409-17. PubMed ID: 20937523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anticoagulation in cirrhosis patients: what don't we know?
    Northup PG; Intagliata NM
    Liver Int; 2011 Jan; 31(1):4-6. PubMed ID: 21092072
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmacological activities of heparin chains: should our past knowledge be revised?
    Agnelli G
    Haemostasis; 1996; 26 Suppl 2():2-9. PubMed ID: 8707164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma levels of enoxaparin oligosaccharides, antifactor-Xa and thrombin generation in patients undergoing haemodialysis.
    Batt TJ; Lincz LF; Prasad R; Patel RP; Shastri M; Lioufas N; Smith AG; Jose MD
    Blood Coagul Fibrinolysis; 2020 Mar; 31(2):152-159. PubMed ID: 31990754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients.
    Haas CE; Nelsen JL; Raghavendran K; Mihalko W; Beres J; Ma Q; Forrest A
    J Trauma; 2005 Dec; 59(6):1336-43; discussion 1343-4. PubMed ID: 16394906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The heparin-mobilisable pool of platelet factor 4: a comparison of intravenous and subcutaneous heparin and Kabi heparin fragment 2165.
    O'Brien JR; Etherington MD; Pashley MA
    Thromb Haemost; 1985 Dec; 54(4):735-8. PubMed ID: 4089807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.